Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 2/20 | 0.39 |
| ▸ | HTR2B | P41595 | 2/20 | 0.39 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.39 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.39 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.39 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.39 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.39 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.39 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15686696 | 0.89 | HTR2C (0.40) | HTR2CHTR2BGABRA1GABRG2GABRB3 | |
| SCHEMBL19682349 | 0.85 | SLC9A1 (0.37) | HTR2CHTR2BMTNR1BMTNR1AITGB2 | |
| SCHEMBL4447693 | 0.85 | HTR2A (0.41) | HTR2CHTR2BLMNACYP1A2CYP3A4 | |
| SCHEMBL24469522 | 0.85 | HTR2A (0.41) | HTR2CHTR2BLMNACYP1A2CYP3A4 | |
| SCHEMBL29793765 | 0.85 | HTR2A (0.41) | HTR2CHTR2BLMNACYP1A2CYP3A4 | |
| Hydrochloric Acid SCHEMBL29042936 | 0.84 | ALDH1A1 (0.41) | HTR2CHTR2BLMNACYP1A2CYP3A4 | |
| Hydrochloric Acid SCHEMBL22836840 | 0.84 | ALDH1A1 (0.41) | HTR2CHTR2BLMNACYP1A2CYP3A4 | |
| Hydrochloric Acid SCHEMBL22836841 | 0.84 | ALDH1A1 (0.41) | HTR2CHTR2BLMNACYP1A2CYP3A4 | |
| SCHEMBL6948697 | 0.81 | MTNR1B (0.35) | HTR2CHTR2BMTNR1BMTNR1AITGB2 | |
| SCHEMBL24367970 | 0.80 | SMN1; SMN2 (0.44) | HTR2CHTR2BGABRA1GABRG2GABRB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240208968-A1 | ALPHA V BETA 6 AND ALPHA V BETA 1 INTEGRIN INHIBITORS AND USES THEREOF | DICE MOLECULES SV, INC. | 2024-06-27 | — | — | US | disclosed |
| US-20240208968-A1 | ALPHA V BETA 6 AND ALPHA V BETA 1 INTEGRIN INHIBITORS AND USES THEREOF | DICE MOLECULES SV, INC. | 2024-06-27 | — | — | US | disclosed |
| US-20240199604-A1 | SUPRAMOLECULAR POLYMER THERAPEUTICS AND DIAGNOSTICS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-06-20 | — | — | US | disclosed |
| US-11912668-B2 | GCN2 and perk kinase inhibitors and methods of use thereof | DECIPHERA PHARMACEUTICALS, LLC (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912668-B2 | GCN2 and perk kinase inhibitors and methods of use thereof | DECIPHERA PHARMACEUTICALS, LLC (US) | 2024-02-27 | — | — | US | disclosed |
| US-20230399319-A1 | Acylsulfamide Compound and Pharmaceutical Use Therefor | JAPAN TOBACCO INC. (JP) | 2023-12-14 | — | — | US | disclosed |
| US-20230399319-A1 | Acylsulfamide Compound and Pharmaceutical Use Therefor | JAPAN TOBACCO INC. (JP) | 2023-12-14 | — | — | US | disclosed |
| EP-3901147-B1 | ACYLAMINO BRIDGED HETEROCYCLIC COMPOUND, AND COMPOSITION AND APPLICATION THEREOF | BEIJING SCITECH MQ PHARMACEUTICALS LTD (CN) | 2023-11-22 | — | — | EP | disclosed |
| WO-2023196975-A1 | COMPOUNDS THAT INTERACT WITH RAS SUPERFAMILY PROTEINS FOR TREATMENT OF CANCERS, INFLAMMATORY DISEASES, RASOPATHIES, AND FIBROTIC DISEASE | SHY THERAPEUTICS, LLC (US) | 2023-10-12 | — | — | WO | disclosed |
| WO-2023158795-A1 | INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF | ACCENT THERAPEUTICS, INC. (US) | 2023-08-24 | — | — | WO | disclosed |
| US-20090124612-A1 | Fused heterocyclic derivatives and methods of use | AMGEN INC. (US) | 2009-05-14 | — | — | US | disclosed |
| US-20090124609-A1 | Fused heterocyclic derivatives and methods of use | AMGEN INC. (US) | 2009-05-14 | — | — | US | disclosed |
| US-7504402-B2 | Triazole derivatives as inhibitors of 11-β-hydroxysteroid dehydrogenase-1 | MERCK & CO., INC. (US) | 2009-03-17 | — | — | US | disclosed |
| US-7504402-B2 | Triazole derivatives as inhibitors of 11-β-hydroxysteroid dehydrogenase-1 | MERCK & CO., INC. (US) | 2009-03-17 | — | — | US | disclosed |
| US-7504411-B2 | 2,3,6-Trisubstituted-4-pyrimidone derivatives | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-03-17 | — | — | US | disclosed |
| US-7504411-B2 | 2,3,6-Trisubstituted-4-pyrimidone derivatives | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-03-17 | — | — | US | disclosed |
| EP-1633748-B1 | QUINOLINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS | GLAXO GROUP LTD (GB) | 2008-03-05 | — | — | EP | disclosed |
| US-7326705-B2 | Heterocyclic sodium/proton exchange inhibitors and method | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-02-05 | — | — | US | disclosed |
| US-20070142373-A1 | Quinoline derivatives as phosphodiesterase inhibitors | GLAXO GROUP LIMITED (GB) | 2007-06-21 | — | — | US | disclosed |
| WO-2007061360-A2 | NOVEL 3-BICYCLOCARBONYLAMINOPYRIDINE-2-CARBOXAMIDES OR 3-BICYCLOCARBONYLAMINOPYRAZINE-2-CARBOXAMIDES | ASTRAZENECA AB (SE) | 2007-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240199604-A1 | SUPRAMOLECULAR POLYMER THERAPEUTICS AND DIAGNOSTICS | MAPT, HTT, PSEN1 | HTR2C 4449/4885HTR2B 3833/4885GABRA1 3342/4885 |
| US-20240208968-A1 | ALPHA V BETA 6 AND ALPHA V BETA 1 INTEGRIN INHIBITORS AND USES THEREOF | ITGB1, ITGA1, ITGAV | HTR2C 4734/4885HTR2B 3181/4885GABRA1 376/4885 |
| US-20090124612-A1 | Fused heterocyclic derivatives and methods of use | HGF, HGFAC, MET | HTR2C 3363/4885HTR2B 3421/4885GABRA1 2292/4885 |
| US-20230399319-A1 | Acylsulfamide Compound and Pharmaceutical Use Therefor | NLRP3, NLRP1, NOD1 | HTR2C 2614/4885HTR2B 1959/4885GABRA1 2080/4885 |
| US-11912668-B2 | GCN2 and perk kinase inhibitors and methods of use thereof | EIF2AK4, GCN1, MAPKAPK2 | HTR2C 3099/4885HTR2B 2683/4885GABRA1 3387/4885 |
| US-20090124609-A1 | Fused heterocyclic derivatives and methods of use | HGF, HGFAC, MET | HTR2C 3363/4885HTR2B 3421/4885GABRA1 2292/4885 |
| US-20070142373-A1 | Quinoline derivatives as phosphodiesterase inhibitors | PDE3B, PDE4B, PDE4A | HTR2C 1379/4885HTR2B 588/4885GABRA1 4235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.